Lyudmila A Bazhenova

Nov 8, 2024 | tandfonline.com | Byoung Chul Cho |Lyudmila A Bazhenova |Dong-Wan Kim |Sanjay Goel

AbstractAim: We report clinical activity and safety of sitravatinib in patients with advanced cancer from basket cohorts with specific molecular alterations, in a Phase Ib study. Materials & methods: Patients with advanced solid tumors harboring amplification, mutation, or rearrangement of MET, AXL, RET, NTRK, DDR2, KDR, PDGFRA, KIT or CBL received sitravatinib once daily. Primary end point was confirmed objective response rate (ORR).

Aug 8, 2024 | onclive.com | Lyudmila A Bazhenova

Lyudmila A. Bazhenova, MD, clinical professor, medicine, The University of California, San Diego (UCSD); medical oncologist, Moores Cancer Center, UCSD Health, discusses updated efficacy data from the phase 2 TRUST-I study (NCT04395677) investigating taletrectinib (AB-106) in patients with ROS1-positive advanced or metastatic non–small cell lung cancer (NSCLC) and highlights the agent's potential role in the NSCLC treatment paradigm.

Aug 5, 2024 | onclive.com | Lyudmila A Bazhenova

CommentaryVideoAugust 5, 2024Author(s):Fact checked by:Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research. Lyudmila A. Bazhenova, MD, clinical professor, medicine, The University of California, San Diego (UCSD); medical oncologist, Moores Cancer Center, UCSD Health, discusses steps that the lung cancer field can take to improve biomarker research and increase patient responses to immunotherapy regimens.

May 22, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Adverse Events Associated With TKIs in HER2-Mutated NSCLCD. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

May 15, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities PersistDr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate CancerDr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCCDarolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC